In this issue:
Oral iron and exercise capacity in HFREF with iron deficiency
Ularitide and CV mortality in acute HF
Association between HIV and HF risk
Models for predicting death in ambulatory HF patients
Spironolactone and mortality/HF risk in advanced chronic kidney disease
No benefit of bosentan in HFPEF with pulmonary hypertension
More thromboembolism with dabigatran than phenprocoumon in LVAD patients
Patient-reported outcomes of vericiguat for HFPEF
Time-to-furosemide and mortality in hospitalised acute HF
Reduced HF and death risk with SGLT-2 inhibitors
Please login below to download this issue (PDF)